Accomplished sports woman Jo Soper, Director and Founder of Beach Gym Personal Training speaks candidly of how NovoTHOR at Laser Therapy Sydney helped to relieve her chronic back pain and sciatica. After 10 sessions she was able to stop the analgesics, anti-inflammatories, opioids and nerve pain medication.
More NovoTHOR Testimonials | NovoTHOR Treatment Locations
View current photobiomodulation therapy training dates in your location.
Doctor Tom Incledon shares how NovoTHOR light therapy is being used at Causenta in Scottsdale, Arizona to help their patients feel and heal better.
NovoTHOR Testimonials | NovoTHOR Treatment Locations
View current photobiomodulation therapy training dates in your location.
“I’m 34 years old and was diagnosed with severe Rheumatoid Arthritis 18 years ago, to the point during flares (often for months at a time), the pain and inflammation was so severe that I’ve been bedridden or had difficulty doing simple tasks such as walking, driving, turning door knobs/opening jars, eating (when I couldn’t bend my elbow enough to reach a spoon or fork to my mouth), etc. Even when I wasn’t experiencing a flare up, I more often than not experienced joint stiffness and moderate difficulty/pain walking and moving in any capacity. With a few notable periods of exception, it was rare that I experienced little to no pain or inflammation, even with the use of oral steroids, drugs (e.g., Humira, Enbrel), or first line treatments (Methotrexate).
Over the years I’ve sustained significant joint damage in my feet, knees, hands, wrists and right elbow, resulting in joint deformation and significant loss of range of motion.
Historically my flares have been worse during fall/winter months and usually start like clockwork in early October, often lasting into March/April. Continue reading
“Each attendance brings something new to think about as our own learning process and experience is evolving. It is always a pleasure to hear about new applications. James has the gift of bringing complicated material in a comprehensive way and adapts his lecture to the need of the group. ”
Beatrijs Deruyter, LTH, MSc, PhDs
Private Dental Practice
Liedekerke, Belgium
View current photobiomodulation therapy training dates in your location.
“Compliment to the training and work you do. It’s making me feel very motivated for my work with my veterinary THOR! Thank you again!”
Gina Voglar
Doctor of Veterinary Medicine
HouseCallVet
Auckland, New Zealand
View current photobiomodulation therapy training dates in your location.
SEATTLE, June 12, 2019 /PRNewswire/ — LumiThera, Inc. and Product Creation Studio today announced that LumiThera’s Valeda Light Delivery System has been honored with a silver award in the 21st Annual Medical Design Excellence Awards competition. The 2019 winners were announced at the MDEA Ceremony on Tuesday, June 11, 2019 in conjunction with the MD&M East event in New York, New York.
LumiThera, Inc. is a leader in the use of photobiomodulation for the treatment of acute and chronic ocular diseases and disorders. Age-related macular degeneration (AMD) is the leading cause of blindness in adults over 65. Product Creation Studio worked with LumiThera from product concept through transfer to manufacturing to design and engineer a medical device that would accurately, safely, and effectively treat patients suffering from dry AMD. The resulting Valeda Light Delivery System is currently the only approved treatment using Photobiomodulation for dry age-related macular degeneration in the European Union.
The MDEA are the medtech industry’s premier design competition committed to recognizing significant achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility. The awards program celebrates the accomplishments of the medical device manufacturers, their suppliers, and the many people behind the scenes—engineers, scientists, designers, and clinicians—who are responsible for the cutting-edge products that are saving lives; improving patient healthcare; and transforming medtech—one innovation at a time.
“This award recognizes the efforts of the LumiThera and the Product Creation teams who have worked diligently to deliver a life changing treatment for those suffering from dry AMD,” said Clark Tedford, PhD, CEO and President. “We are pleased to bring the Valeda Light Delivery System to the ophthalmic market and offer dry AMD patients a treatment for this debilitating disease.”
“Product Creation Studio’s collaboration with LumiThera embodies what our organization is about: empowering innovators with the right design and development services at the right time to deliver products with impact,” Scott Thielman, Chief Technology officer of Product Creation Studio, said. “The Valeda Light Delivery System is a breakthrough product that makes a meaningful difference for patients and their families. It has been an honor to support the LumiThera team with comprehensive engineering and design services from the company’s early days through production.”
The 2019 MDEA Juror Panel selected 44 exceptional finalists in nine medical technology product categories. Products were judged based on design and engineering innovation; function and user-related innovation; patient benefits; business benefits; and overall benefit to the healthcare system. Unlike other design competitions that are merely styling contests, the MDEA jury is comprised of a balance of practicing doctors, nurses, and technicians alongside industrial designers, engineers, manufacturers, and human factors experts.
View the press release on Lumithera website at www.lumithera.com
Disclosure: I am an investor in Lumithera a) because it successfully treats an unmet medical need, (dry AMD) b) I think it will be the first billion dollar photobiomodulation company.
A hundred million adults in the United States are affected by chronic pain and $600 billion a year is spent on in health care, direct health care costs and lost productivity because of pain.
49,000 people from opioids in 2017, 19,000 of which were from prescribed opioids for pain relief.
We believe that Photobiomodulation therapy can help reduce the prescribing of opioid medication for pain relief and we wish to draw attention to the Congress and health care policymakers, NIH and CMS, about this potentially valuable tool.
Learn more at CongressPBM.com
Watch the Congressional Briefing Highlight Video
Read James Carroll’s Speech to Congress on citizenoversight.blogspot.com
View current photobiomodulation therapy training dates in your location.
U.S. CONGRESSIONAL BRIEFING. Ending Opioid Use – Washington DC
James Carroll presented evidence to Congress on the effectiveness of PBM for treating pain and where it can be used in place of opioids. Prof. Praveen Arany explained how and why it works, and Annette Quinn RN gave her first hand experience in treating over 854 patients with Oral Mucositis.
Learn more at CongressPBM.com
Watch James Carroll’s Congress speech on ending opioid use with Photobiomodulation
Read James Carroll’s Speech to Congress on citizenoversight.blogspot.com
View current photobiomodulation therapy training dates in your location.
36 Photobiomodulation therapy papers published in February 2018. Highlights include:
This 15 minute video starts with an overview of Photobiomodulation and low level light therapy. Later in the presentation James introduces the Lumithera treatment for Dry Age related Macular Degeneration (AMD).
The paper “High-intensity versus low-level laser therapy in the treatment of patients with knee osteoarthritis: a randomized controlled trial” Kheshie et al 2014 pitches the 3B BTL laser against the HIRO class IV “High intensity” laser. The results appear to show that the HIRO class IV “High intensity laser” was more effective than the “Low Level Laser”. HOWEVER, the HIRO class IV “High intensity” laser was delivered over a large area (not adequately defined but approx 100cm2 by my estimation) so the intensity was actually very low (about 13mW/cm2 which is less than most LED systems), and the 3B BTL “Low Level Laser” was actually very high (4 x 200mW small, high intensity beams) and were held stationary on the patella for over half an hour, YES, HALF AN HOUR IN ONE SPOT! This is insane.
This paper leads people to think that the class IV Hiro laser was more effective because it was higher intensity when in fact the beam distribution meant the average intensity distribution was low (13mW/cm2). The 3B laser was not so effective because it was held stationary such that it would cause an overdose. If the 3B laser treatment had been delivered in using same scanning technique as the class IV then they would likely have achieved the same result. (I am not a fan of scanning because you can never be sure how much energy you have delivered to an area, better to use a low intensity device and hold it still in my view).
This paper misdirects the reader towards favouring class IV lasers rather than 3b or LED by misinforming the reader.
The title of last months PMLS editorial was Low Level Laser Therapy (LLLT) and World Association for Laser Therapy (WALT) Dosage Recommendations. Written by the Scientific Secretary Prof. Jan Bjordal. He describes how far we have come and the importance of the WALT dosage recommendations. No abstract is available for editorials so I have prepared one for you below. Continue reading
A paper titled ”The Effectiveness of Therapeutic Class IV (10 W) Laser Treatment for Epicondylitis” [ref] showed that 10 Watt Class IV laser (mixed 8W 970nm, 2W 810) was successful in reducing pain and improving function in an RCT with 15 patients, and that there was good statistical significance at 6 months following a course of 6 treatments.
The claim by class IV laser manufacturers is that class IV lasers are better (faster, deeper and more effective) than Class 3b and LED systems. Conversely the 3B laser and LED manufacturers argue that less power density is more effective because delivering energy too quickly can overdose tissues and class IV lasers might burn the skin.
Throughout this paper there are marketing messages claiming the advantages of shorter treatment times than low power LLLT systems and of course the title shouts “10 Watt Class IV laser” just in case the reader is in any doubt that more power is what you need.
Regular readers of this column know my obsession with irradiation parameters, particularly dose rate effects (W/cm2) and will not be surprised to learn that I deconstruced the irradiation parameters used in this trial . Surprise, surprise they were the same low irradiance levels typically used by 3B lasers and LED systems, if not less and the treatment time was longer too.
Yes, it was a 10 Watt laser and yes, 3,000 joules was delivered, however it had a large beam area and treatment was delivered over (45cm2) in a “painting fashion”. The fluence (dose) was 6.6 Joules/cm2 and the power density was a tiny 22mW/cm2, consequently treatment time was a hefty 5 mins.
The average irradiance was not disclosed in the paper and the reader is directed to think that more power is quicker.
P.S. research trials with 3B lasers are typically 30 seconds to 3 mins and our recommended treatment is 1 min with a large LED cluster to the lateral epicondyle and 30 seconds for any related trigger points.
The Treatment Protocol Library is available only to THOR Customers and/or people who have attended a THOR training course in the last 3 years. All treatments are based on our four step method which includes treatment of the injury, trigger points, lymphatics and nerve roots.
Take a look to see how it works and let us know what you think.
Access Treatment Protocol Library
Paul Harper chose NovoTHOR light therapy at Laser Therapy Sydney to help reduce the pain of his tennis elbow. Not only did it get rid of the pain in his arm but surprisingly he found that there were additional side-benefits too.
More NovoTHOR Testimonials | NovoTHOR Treatment Locations
View current photobiomodulation therapy training dates in your location.
Dr Roberta Chow PhD and Lydia Feng talk about the use of light and lasers for relief of chronic pain. The THOR handheld unit and NovoTHOR light-pod can be used to reduce the need for medication and delay the need for surgery without any side-effects.
View current photobiomodulation therapy training dates in your location.
UK and Ireland dates
USA and Canada dates
Australia and NZ dates
Rest Of World dates
Featured Testimonials
THOR on Facebook
THOR on Twitter
THOR on LinkedIn
THOR on Instagram
THOR on YouTube